UTRS (Minerva Surgical) Gross Margin %: 51.97% (As of Sep. 2023)


What is Minerva Surgical Gross Margin %?

Minerva Surgical UTRS -99.00% Gross Margin % is 51.97% as of Sep. 2023.

Gross Margin % is calculated as gross profit divided by its revenue. Minerva Surgical's Gross Profit for the three months ended in Sep. 2023 was $6.22 Mil. Minerva Surgical's Revenue for the three months ended in Sep. 2023 was $11.97 Mil. Therefore, Minerva Surgical's Gross Margin % for the quarter that ended in Sep. 2023 was 51.97%.


The historical rank and industry rank for Minerva Surgical's Gross Margin % or its related term are showing as below:


UTRS's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 52.07
* Ranked among companies with meaningful Gross Margin % only.

Minerva Surgical had a gross margin of 51.97% for the quarter that ended in Sep. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Minerva Surgical was 0.00% per year.

Minerva Surgical  (OTCPK:UTRS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Minerva Surgical had a gross margin of 51.97% for the quarter that ended in Sep. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Minerva Surgical Gross Margin % Related Terms

Minerva Surgical Gross Margin % Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Gross Margin % Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Margin %
45.38 50.62 58.58 54.17

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.12 53.40 55.97 55.28 51.97

UTRS vs PAVM, ELUT, COCH: Gross Margin % Comparison

For the Medical Devices subindustry, Minerva Surgical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Surgical Gross Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Minerva Surgical's Gross Margin % falls into.


Minerva Surgical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Minerva Surgical's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=27.2 / 50.294
=(Revenue - Cost of Goods Sold) / Revenue
=(50.294 - 23.052) / 50.294
=54.17 %

Minerva Surgical's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=6.2 / 11.965
=(Revenue - Cost of Goods Sold) / Revenue
=(11.965 - 5.747) / 11.965
=51.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 51.97% mean?
Minerva Surgical (UTRS) has a Gross Margin % of 51.97% as of Sep. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on Minerva Surgical and its competitors.
Is Minerva Surgical's Gross Margin % too high?
Minerva Surgical's current Gross Margin % is 51.97%. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Minerva Surgical's value of 51.97% is 0.2% below this industry median.
How does Minerva Surgical's Gross Margin % compare to PAVM and ELUT?
Minerva Surgical's Gross Margin % of 51.97% can be compared against companies in the Medical Devices & Instruments industry. The industry median Gross Margin % is 52.07. Minerva Surgical's value of 51.97% is 0.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minerva Surgical's current Gross Margin % of 51.97% is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Minerva Surgical and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minerva Surgical's current Gross Margin % is 51.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current Gross Margin % of 51.97%. The current Gross Margin % is 51.97% and 0.2% below the Medical Devices & Instruments industry median of 52.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current Gross Margin % is 51.97% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.